These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 37627175)

  • 21. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
    Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
    Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting RET alterations in cancer: Recent progress and future directions.
    Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
    Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
    Nagasaka M; Brazel D; Baca Y; Xiu J; Al-Hallak MN; Kim C; Nieva J; Swensen JJ; Spetzler D; Korn WM; Socinski MA; Raez LE; Halmos B; Ou SI
    Transl Oncol; 2023 Oct; 36():101744. PubMed ID: 37516008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
    Hamidi S; Hu MI
    Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting RET alterations in non-small cell lung cancer.
    Nishikawa G; Klein MA
    Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 30. Precious Gene: The Application of RET-Altered Inhibitors.
    Gou Q; Gan X; Li L; Gou Q; Zhang T
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selpercatinib and capmatinib combination promotes sustained complete response in novel
    Leite CA; Carvalho RP; da Costa FM; Medeiros AK; Schutz FA; William WN
    Front Oncol; 2023; 13():1264231. PubMed ID: 37876974
    [No Abstract]   [Full Text] [Related]  

  • 33. RET signaling pathway and RET inhibitors in human cancer.
    Regua AT; Najjar M; Lo HW
    Front Oncol; 2022; 12():932353. PubMed ID: 35957881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
    Kucharczyk T; Krawczyk P; Kowalski DM; Płużański A; Kubiatowski T; Kalinka E
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
    Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
    Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development.
    Thein KZ; Myat YM; Park BS; Panigrahi K; Kummar S
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. State-of-the-Art Strategies for Targeting
    Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F
    J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.